APRINOIA Therapeutics Closes US$11 Million Series B Financing to Advance Its Tau PET Imaging Tracer and Tau Therapeutic Programs for Alzheimer’s Disease

January 15, 2018

Responsive image

TAIPEI, Taiwan, Jan. 16, 2018 /PRNewswire/ — APRINOIA Therapeutics Inc., a clinical-stage neuroscience biotech company, focuses on tau, alpha-synuclein, and novel targets for neurodegenerative diseases, announces today the completion of its US$11.1 million Series B round. The Series B…

Category: Precious Metals